Allergy Therapeutics (AGY.L) Stock Price

£5.5 4.3%

Sign up
to add to portfolio

AI Score

Hold
  • Alternative

    5
  • Fundamental

    0
  • Technical

    5

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Allergy Therapeutics, AI stock picks, stock alerts and much more.

Sign up

AGY.L AI Stock Analysis

AI stock analysis for AGY.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Allergy Therapeutics (AGY.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Allergy Therapeutics (AGY.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Allergy Therapeutics (AGY.L), currently trading at £5.5, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About AGY.L

LSE
  • Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments.

  • Symbol

    AGY.L

  • Market

    LSE

  • Industry

    Drug Manufacturers - Specialty & Generic

  • Market Cap

    345.3M

Similar Stocks

0A4X.L DMK Pharmaceuticals
0A4X.L
$0.0009
0.00%
6
STX.L Shield Therapeutics
STX.L
£3.01
11%
4
INDV.L Indivior PLC
INDV.L
£843.5
3.7%
5
HLN.L Haleon plc
HLN.L
£377.4
0.3%
6
HCM.L HUTCHMED (China) Limited
HCM.L
£226.2
2.1%
5

AGY.L Alternative Data

Web Traffic

Allergy Therapeutics receives an estimated 0 monthly visitors to allergytherapeutics.com.

  • Web Traffic

    0

  • Change from Previous Month

    100%

  • 3 Month Change

    100%

News Mentions

Allergy Therapeutics was mentioned 1 times in the news yesterday.

  • News Mentions

    1

  • Daily Change

    66.7%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Instagram Followers

Allergy Therapeutics has 56 Instagram Followers on its main Instagram account, up by 1.8% over the last month.

  • Instagram Followers

    56

  • Daily Change

    0%

  • 1 Month Change

    1.8%

  • 3 Month Change

    3.7%

Youtube Subscribers

Allergy Therapeutics has 26 subscribers on its main Youtube channel, up by 4% over the last month.

  • Youtube Subscribers

    26

  • Daily Change

    0%

  • 1 Month Change

    4%

  • 3 Month Change

    4%

LinkedIn Followers

10,426 are following Allergy Therapeutics on LinkedIn, up by 1.5% over the last month.

  • LinkedIn Followers

    10426

  • Daily Change

    0%

  • 1 Month Change

    1.5%

  • 3 Month Change

    3.7%

LinkedIn Employees

According to LinkedIn, Allergy Therapeutics has 361 employees, down by -0.6% over the last month.

  • LinkedIn Employees

    361

  • Daily Change

    0%

  • 1 Month Change

    0.6%

  • 3 Month Change

    0.3%

Business Outlook
  • Business Outlook

    34

  • Change from Previous Month

    36%

  • 3 Month Change

    0%

  • YoY Change

    0%

AGY.L Financials

AGY.L Key Metrics
  • Total Revenue

    £21.6M

  • Net Income

    -£24.6M

  • Earnings per Share

    -£0.0065

  • Free cash flow

    -£23.4M

  • EBITDA

    -£21M

  • EBITDA Ratio

    -0.972858

  • Total Assets

    £64.8M

AGY.L 2-year Revenue & Income
AGY.L 2-year Free Cash Flow

AGY.L Technicals

AGY.L SMA
AGY.L RSI

FAQ

What's the current price of Allergy Therapeutics (AGY.L) Stock?
The price of an Allergy Therapeutics (AGY.L) share is £5.5.

What's the market cap of Allergy Therapeutics?
The current market cap of Allergy Therapeutics is 345.3M.

Should I buy or sell AGY.L?
Allergy Therapeutics shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Allergy Therapeutics is better viewed as a hold or accumulate position while waiting for further developments.

Is Allergy Therapeutics a good investment?
The current analysis of Allergy Therapeutics' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Allergy Therapeutics' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.

Is now a good time to buy Allergy Therapeutics (AGY.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Allergy Therapeutics stock is currently neutral, suggesting a cautious approach might be wise.

What are some stocks similar to Allergy Therapeutics (AGY.L) that investors often compare it to?
Allergy Therapeutics (AGY.L) is often compared to similar stocks such as DMK Pharmaceuticals, Shield Therapeutics, Indivior PLC, Haleon plc and HUTCHMED (China) Limited.

What is the forecast for Allergy Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Allergy Therapeutics' stock price to be around £5.24 in 2026. Starting from the current price of £5.5, this represents a 4.8% change in price, indicating a bearish outlook for the stock.

How to buy Allergy Therapeutics (AGY.L) Stock?
Allergy Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Allergy Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.